AR017513A1 - COMBINED PHARMACEUTICAL PREPARATION CONTAINING AN EXCHANGER OF THE EXCHANGER BETWEEN SODIUM AND HYDROGEN AND COMMERCIAL CONTAINER INTENDED FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES - Google Patents

COMBINED PHARMACEUTICAL PREPARATION CONTAINING AN EXCHANGER OF THE EXCHANGER BETWEEN SODIUM AND HYDROGEN AND COMMERCIAL CONTAINER INTENDED FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES

Info

Publication number
AR017513A1
AR017513A1 ARP980104222A ARP980104222A AR017513A1 AR 017513 A1 AR017513 A1 AR 017513A1 AR P980104222 A ARP980104222 A AR P980104222A AR P980104222 A ARP980104222 A AR P980104222A AR 017513 A1 AR017513 A1 AR 017513A1
Authority
AR
Argentina
Prior art keywords
exchanger
treatment
pharmaceutical preparation
sodium
hydrogen
Prior art date
Application number
ARP980104222A
Other languages
Spanish (es)
Original Assignee
Gompel Marie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gompel Marie filed Critical Gompel Marie
Publication of AR017513A1 publication Critical patent/AR017513A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Preparado farmacéutico, caracterizado porque contiene un inhibidor del intercambiador entre Na+ y H+ y una sustancia activa sobre el corazon y lacirculacion. En este caso, tales combinaciones de un inhibidor del NHE pueden constar de uno o varios componentes terapéuticos activos sobre lacirculacion. La combinacion de las propiedades protectoras del corazon con terapias conocidas de enfermedades cardiocirculatorias conduce por unaparte a un mejoramiento de la calidad del tratamiento y por otra parte, en numerosas combinaciones, a un refuerzo aditivo o potenciador de losefectos sobre el corazon y la circulacion de los componentes individuales de efecto, tomados a solas. Un envase comercial que comprende dichopreparado farmacéutico combinado destinado al tratamiento de enfermedades cardiocirculatorias.Pharmaceutical preparation, characterized in that it contains an inhibitor of the exchanger between Na + and H + and an active substance on the heart and circulation. In this case, such combinations of an NHE inhibitor may consist of one or more therapeutic components active on circulation. The combination of the protective properties of the heart with known therapies of cardiocirculatory diseases leads by a part to an improvement in the quality of the treatment and on the other hand, in numerous combinations, to an additive or enhancer reinforcement of the effects on the heart and the circulation of the individual components of effect, taken alone. A commercial package comprising combined pharmaceutical dichopreparate intended for the treatment of cardiocirculatory diseases.

ARP980104222A 1997-08-27 1998-08-25 COMBINED PHARMACEUTICAL PREPARATION CONTAINING AN EXCHANGER OF THE EXCHANGER BETWEEN SODIUM AND HYDROGEN AND COMMERCIAL CONTAINER INTENDED FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES AR017513A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19737224A DE19737224A1 (en) 1997-08-27 1997-08-27 Pharmaceutical preparation for cardiovascular treatment

Publications (1)

Publication Number Publication Date
AR017513A1 true AR017513A1 (en) 2001-09-12

Family

ID=7840257

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104222A AR017513A1 (en) 1997-08-27 1998-08-25 COMBINED PHARMACEUTICAL PREPARATION CONTAINING AN EXCHANGER OF THE EXCHANGER BETWEEN SODIUM AND HYDROGEN AND COMMERCIAL CONTAINER INTENDED FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES

Country Status (23)

Country Link
US (1) US6348476B1 (en)
EP (1) EP0937464B1 (en)
JP (1) JP4436940B2 (en)
KR (1) KR19990023904A (en)
CN (1) CN1172665C (en)
AR (1) AR017513A1 (en)
AU (1) AU738598B2 (en)
BR (1) BR9803233A (en)
CA (1) CA2245776A1 (en)
CZ (1) CZ270998A3 (en)
DE (1) DE19737224A1 (en)
HK (1) HK1018211A1 (en)
HR (1) HRP980464A2 (en)
HU (1) HUP9801924A3 (en)
IL (1) IL125913A0 (en)
NO (1) NO320264B1 (en)
NZ (1) NZ331533A (en)
PL (1) PL195566B1 (en)
RU (1) RU2227751C2 (en)
SK (1) SK116798A3 (en)
TR (1) TR199801661A2 (en)
TW (1) TW589175B (en)
ZA (1) ZA987723B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945302A1 (en) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenyl derivatives as NHE-3 inhibitors
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6844361B2 (en) 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
ATE520398T1 (en) * 2002-02-04 2011-09-15 Sanofi Aventis Deutschland COMBINATION PREPARATION OF THE SODIUM-HYDROGEN EXCHANGE INHIBITOR CARIPORIDE WITH RAMIPRIL FOR PREVENTING OR INHIBITING HEART FAILURE
US7375138B2 (en) * 2002-05-18 2008-05-20 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
FR2840302B1 (en) * 2002-06-03 2004-07-16 Aventis Pharma Sa ISOINDOLONE DERIVATIVES, PREPARATION METHOD AND INTERMEDIARY THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
US6878748B2 (en) 2002-06-13 2005-04-12 Aventis Pharma Deutschland Gmbh Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them
MXPA05011840A (en) * 2003-05-06 2006-01-26 Merck Patent Gmbh Method for crystallizing guanidinium salts.
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
DE10356717A1 (en) * 2003-12-02 2005-07-07 Aventis Pharma Deutschland Gmbh Process for the preparation of (3-oxo-2,3-dihydro-1H-isoindol-1-yl) -acetylguanidine derivatives
US7531569B2 (en) * 2003-12-02 2009-05-12 Sanofi-Aventis Deutschland Gmbh Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
AU2005301989A1 (en) * 2004-11-05 2006-05-11 King Pharmaceuticals Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3960165A1 (en) * 2020-08-25 2022-03-02 Fondation EspeRare Nhe-1 inhibitors for the treatment of coronavirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556673B1 (en) 1992-02-15 1997-09-17 Hoechst Aktiengesellschaft Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as medicaments containing them
DE59305042D1 (en) * 1992-09-22 1997-02-20 Hoechst Ag Benzoylguanidines, processes for their preparation and their use as antiarrhythmics
DE4328869A1 (en) 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
DE4421536A1 (en) 1994-06-20 1995-12-21 Hoechst Ag Phenyl-substituted alkenylcarboxylic acid guanidines bearing perfluoroalkyl groups, processes for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them
DE4422685A1 (en) 1994-06-29 1996-01-04 Hoechst Ag Ortho-amino-substituted benzoylguanidines, processes for their preparation, their use as medicaments or diagnostic agents and medicaments containing them
DE4432106A1 (en) 1994-09-09 1996-03-14 Hoechst Ag Heterocyclic N-oxide-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic, medicament containing them and intermediates for their preparation
DE19741635A1 (en) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamides, process for their preparation and their use as a medicament

Also Published As

Publication number Publication date
CN1209316A (en) 1999-03-03
IL125913A0 (en) 1999-04-11
NO983926L (en) 1999-03-01
PL195566B1 (en) 2007-10-31
EP0937464B1 (en) 2012-07-11
SK116798A3 (en) 1999-03-12
BR9803233A (en) 2000-05-02
JPH11139990A (en) 1999-05-25
NZ331533A (en) 2000-04-28
PL328251A1 (en) 1999-03-01
HUP9801924A2 (en) 2000-02-28
ZA987723B (en) 1999-03-01
NO983926D0 (en) 1998-08-26
TW589175B (en) 2004-06-01
US6348476B1 (en) 2002-02-19
EP0937464A3 (en) 2003-09-24
NO320264B1 (en) 2005-11-14
CZ270998A3 (en) 1999-03-17
EP0937464A2 (en) 1999-08-25
DE19737224A1 (en) 1999-03-18
HUP9801924A3 (en) 2004-11-29
KR19990023904A (en) 1999-03-25
CN1172665C (en) 2004-10-27
HRP980464A2 (en) 1999-06-30
CA2245776A1 (en) 1999-02-27
RU2227751C2 (en) 2004-04-27
HK1018211A1 (en) 1999-12-17
TR199801661A2 (en) 1999-03-22
AU8190898A (en) 1999-03-11
AU738598B2 (en) 2001-09-20
HU9801924D0 (en) 1998-10-28
JP4436940B2 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
AR017513A1 (en) COMBINED PHARMACEUTICAL PREPARATION CONTAINING AN EXCHANGER OF THE EXCHANGER BETWEEN SODIUM AND HYDROGEN AND COMMERCIAL CONTAINER INTENDED FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES
ES2036553T3 (en) PHARMACEUTICAL COMPOSITIONS THAT HAVE ANTINEOPLASTIC ACTIVITY.
UY25791A1 (en) COMBINATIONS FOR DIABETES
CO4750836A1 (en) NEW MEDICINES AND USE (1-METHYLETHYL) -8-AZONIABICICLO- [3.2.1] OCTNAO AND ITS USE IN MEDICAL PREPARATIONS
UY30605A1 (en) AUTOCONSERVED WATERPROOF PHARMACEUTICAL COMPOSITIONS
ES2169087T3 (en) ORAL FORMULATIONS OF AN ANTIFUNGIC.
PE20020307A1 (en) HYDROGEL ACTIVATED DRUG DOSAGE FORM
GR3002487T3 (en) Medicament with anti-tumoral action containing hexadecylphosphocholine
ES2058420T3 (en) COMBINED PHARMACEUTICAL PREPARATIONS AND THEIR USE AS ANTINEOPLASIC MEDICINES.
DE3484573D1 (en) PENETRIC TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING N- (2-HYDROXYETHYL) -PYRROLIDONE.
ES2093735T3 (en) MELATONIN DERIVATIVES FOR USE IN SLEEP DISORDERS THERAPY AND IN PRE-ANESTHETIC MEDICATION.
ES2185817T3 (en) ORAL PHARMACEUTICAL DOSAGE FORMS THAT INCLUDE AN INHIBITOR OF THE PUMPS OF PROTONS AND AN AGENT ANTICIDE OR ALGINATE.
MY118164A (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
ES2145913T3 (en) METALOPROTEASE INHIBITORS.
AR027391A1 (en) BOTULIN TOXIN PHARMACEUTICAL COMPOSITIONS
UY29450A1 (en) IMPROVEMENT IN THE PROCEDURES TO CHANGE MYASIS OF LARGE ANIMALS AS BOVINE AND OVINE AND COMPOSITIONS FOR THE PRACTICE OF THIS PROCEDURE AND THE USE OF KNOWN PARASITICIDES FOR THE PREPARATION OF THESE C
AR014126A1 (en) USE OF A SOLUBLE BISMUTO SALT, A FIRST ANTIBIOTIC AND A SECOND ANTIBIOTIC AND A PHARMACEUTICAL DOSAGE FORM
BR0214403A (en) Pharmaceutical compositions comprising metformin and glyburide for the treatment of type 2 diabetes mellitus
ES2178048T3 (en) USE OF RIFAXIMINE AS A MEDICINAL PRODUCT FOR THE TREATMENT OF DIARRHEA BY CRYPTOSPORIDIOSIS.
DE69531098D1 (en) PIPERIDINE AND PYRROLIDINE
ES2034926T1 (en) LIQUID ORAL PHARMACEUTICAL COMPOSITIONS WITH ANTI-INFLAMMATORY ACTIVITY.
ES2163795T3 (en) PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND INFECTIONS BY PAPILOMAVIRUS.
ES2056588T3 (en) DISPENSER-DISPENSER AND DOSING PROCEDURE OF A PASTY AND / OR LIQUID PRODUCT.
SE8103369L (en) ANTIPERSPIRANT COMPOSITION CONTAINING AN ALUMINUM CHLORIDE AND AN ALUMINUM ZIRCONIUM HYDROXYCHLORIDE AS ACTIVE INGREDIENTS AND SET TO INHIBIT PERSPIRATION
BR0312782A (en) Composition for the treatment of stains

Legal Events

Date Code Title Description
FB Suspension of granting procedure